S&P 500   4,967.23 (-0.88%)
DOW   37,986.40 (+0.56%)
QQQ   414.65 (-2.07%)
AAPL   165.00 (-1.22%)
MSFT   399.12 (-1.27%)
META   481.07 (-4.13%)
GOOGL   154.09 (-1.23%)
AMZN   174.63 (-2.56%)
TSLA   147.05 (-1.92%)
NVDA   762.00 (-10.00%)
AMD   146.64 (-5.44%)
NIO   3.80 (-5.00%)
BABA   69.07 (+0.28%)
T   16.51 (+1.10%)
F   12.14 (+0.66%)
MU   106.77 (-4.61%)
GE   148.06 (-3.19%)
CGC   7.93 (+1.28%)
DIS   112.61 (+0.16%)
AMC   3.16 (+8.22%)
PFE   26.00 (+2.40%)
PYPL   62.31 (+0.34%)
XOM   119.88 (+1.15%)
S&P 500   4,967.23 (-0.88%)
DOW   37,986.40 (+0.56%)
QQQ   414.65 (-2.07%)
AAPL   165.00 (-1.22%)
MSFT   399.12 (-1.27%)
META   481.07 (-4.13%)
GOOGL   154.09 (-1.23%)
AMZN   174.63 (-2.56%)
TSLA   147.05 (-1.92%)
NVDA   762.00 (-10.00%)
AMD   146.64 (-5.44%)
NIO   3.80 (-5.00%)
BABA   69.07 (+0.28%)
T   16.51 (+1.10%)
F   12.14 (+0.66%)
MU   106.77 (-4.61%)
GE   148.06 (-3.19%)
CGC   7.93 (+1.28%)
DIS   112.61 (+0.16%)
AMC   3.16 (+8.22%)
PFE   26.00 (+2.40%)
PYPL   62.31 (+0.34%)
XOM   119.88 (+1.15%)
S&P 500   4,967.23 (-0.88%)
DOW   37,986.40 (+0.56%)
QQQ   414.65 (-2.07%)
AAPL   165.00 (-1.22%)
MSFT   399.12 (-1.27%)
META   481.07 (-4.13%)
GOOGL   154.09 (-1.23%)
AMZN   174.63 (-2.56%)
TSLA   147.05 (-1.92%)
NVDA   762.00 (-10.00%)
AMD   146.64 (-5.44%)
NIO   3.80 (-5.00%)
BABA   69.07 (+0.28%)
T   16.51 (+1.10%)
F   12.14 (+0.66%)
MU   106.77 (-4.61%)
GE   148.06 (-3.19%)
CGC   7.93 (+1.28%)
DIS   112.61 (+0.16%)
AMC   3.16 (+8.22%)
PFE   26.00 (+2.40%)
PYPL   62.31 (+0.34%)
XOM   119.88 (+1.15%)
S&P 500   4,967.23 (-0.88%)
DOW   37,986.40 (+0.56%)
QQQ   414.65 (-2.07%)
AAPL   165.00 (-1.22%)
MSFT   399.12 (-1.27%)
META   481.07 (-4.13%)
GOOGL   154.09 (-1.23%)
AMZN   174.63 (-2.56%)
TSLA   147.05 (-1.92%)
NVDA   762.00 (-10.00%)
AMD   146.64 (-5.44%)
NIO   3.80 (-5.00%)
BABA   69.07 (+0.28%)
T   16.51 (+1.10%)
F   12.14 (+0.66%)
MU   106.77 (-4.61%)
GE   148.06 (-3.19%)
CGC   7.93 (+1.28%)
DIS   112.61 (+0.16%)
AMC   3.16 (+8.22%)
PFE   26.00 (+2.40%)
PYPL   62.31 (+0.34%)
XOM   119.88 (+1.15%)
Free Trial
NASDAQ:SLS

SELLAS Life Sciences Group (SLS) Stock Price, News & Analysis

→ Tiny Biotech Stock Wins $75 Billion Patent (From Behind the Markets) (Ad)
Free SLS Stock Alerts
$1.54
+0.02 (+1.32%)
(As of 04:00 PM ET)
Compare
Today's Range
$1.47
▼
$1.57
50-Day Range
$0.70
▼
$1.55
52-Week Range
$0.50
▼
$1.91
Volume
1.80 million shs
Average Volume
1.46 million shs
Market Capitalization
$86.66 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.00
Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media

SELLAS Life Sciences Group MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
100.7% Upside
$3.00 Price Target
Short Interest
Bearish
9.37% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank™

New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.73 out of 5 stars

Medical Sector

843rd out of 918 stocks

Pharmaceutical Preparations Industry

382nd out of 417 stocks

See Top Rated MarketRank™ Stocks Here
SLS stock logo

About SELLAS Life Sciences Group Stock (NASDAQ:SLS)

SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. The company is headquartered in New York, New York.

SLS Stock Price History

SLS Stock News Headlines

April 19, 2024 | seekingalpha.com
Sellas Life Sciences Group: A Lottery Ticket With An Estimated 9x Payout
March 28, 2024 | msn.com
SELLAS Life Sciences Group files for $200M mixed shelf
April 19, 2024 | Behind the Markets (Ad)
Tiny Biotech Stock Wins $75 Billion Patent
A little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.
March 28, 2024 | globenewswire.com
SELLAS Life Sciences Reports Full Year 2023 Financial Results and Provides Corporate Update
March 27, 2024 | markets.businessinsider.com
Buy Rating for SELLAS Life Sciences Amid Positive AML Study Results and Strengthened Financials
March 26, 2024 | markets.businessinsider.com
SELLAS Phase 2a Study Of SLS009 In R/r AML Positive; Updates Phase 3 REGAL Study
March 26, 2024 | globenewswire.com
SELLAS Announces Positive Topline Data from the Phase 2a Study of SLS009 in r/r AML and Provides Steering Committee Update on Phase 3 REGAL Study
March 21, 2024 | wsj.com
SELLAS Life Sciences Group Inc.
April 19, 2024 | Behind the Markets (Ad)
Tiny Biotech Stock Wins $75 Billion Patent
A little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.
March 19, 2024 | globenewswire.com
SELLAS Life Sciences Group Announces Closing of $20 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules
March 19, 2024 | globenewswire.com
SELLAS Life Sciences to Host Corporate Update Call on March 26, 2024, at 8:15 am ET
March 16, 2024 | marketwatch.com
Sellas Life Sciences Shares Drop 31% After Direct Offering Prices
March 15, 2024 | msn.com
Geron, Graphite Bio, Immuneering among healthcare movers
March 15, 2024 | msn.com
SELLAS Life Sciences looks to raise $20M in a direct offering
March 15, 2024 | markets.businessinsider.com
Sellas Announces $20 Mln Registered Direct Offering, Concurrent Private Placement
March 15, 2024 | finance.yahoo.com
SELLAS Life Sciences Group Announces $20 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules
March 15, 2024 | globenewswire.com
SELLAS Life Sciences Group Announces $20 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules
March 12, 2024 | seekingalpha.com
Aadi Bioscience Q4 2023 Earnings Preview
March 10, 2024 | investing.com
Sellas Life Sciences Group Inc (SLS)
March 9, 2024 | finanznachrichten.de
SELLAS Life Sciences Group, Inc.: SELLAS Announces Executive Leadership Reorganization and Prioritization of Commercialization Partnerships
March 8, 2024 | globenewswire.com
SELLAS Announces Executive Leadership Reorganization and Prioritization of Commercialization Partnerships
March 7, 2024 | finance.yahoo.com
SLS Mar 2024 4.000 put
March 1, 2024 | finance.yahoo.com
SELLAS Life Sciences Group, Inc. (SLS)
March 1, 2024 | globenewswire.com
SELLAS Life Sciences Delivers Oral Presentation of SLS009 Phase 1 Data for Acute Myeloid Leukemia Patients at 2024 European School of Haematology (ESH) Conference
February 29, 2024 | globenewswire.com
SELLAS Life Sciences to Present SLS009 Phase 1 Data from Acute Myeloid Leukemia Patients at the 2024 European School of Haematology (ESH) Conference: Updated Date and Time
February 22, 2024 | morningstar.com
SELLAS Life Sciences Group Inc
February 16, 2024 | ca.finance.yahoo.com
SLS Feb 2024 0.500 call
See More Headlines
Receive SLS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for SELLAS Life Sciences Group and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/12/2021
Today
4/19/2024
Next Earnings (Estimated)
5/09/2024
Fiscal Year End
12/31/2024
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:SLS
CUSIP
N/A
CIK
1390478
Web
www.sellaslifesciences.com
Phone
(646) 200-5278
Fax
441-400-2875
Employees
17
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$3.00
High Stock Price Target
$3.00
Low Stock Price Target
$3.00
Potential Upside/Downside
+100.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($1.36)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-37,340,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-2,405.54%
Return on Assets
-241.00%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.23
Quick Ratio
0.23

Sales & Book Value

Annual Sales
$1 million
Price / Sales
84.12
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($0.25) per share
Price / Book
-5.98

Miscellaneous

Outstanding Shares
56,270,000
Free Float
55,368,000
Market Cap
$84.12 million
Optionable
Not Optionable
Beta
2.35
(Almost) Everything You Need To Know About The EV Market Cover
(Almost) Everything You Need To Know About The EV Market

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

  • Dr. Angelos M. Stergiou M.D. (Age 48)
    ScD h.c., Founder, President, CEO & Director
    Comp: $921.99k
  • Mr. John Thomas Burns CPA (Age 39)
    Senior VP & CFO
    Comp: $338.45k
  • Ms. Stacy E. Yeung
    VP, Associate General Counsel & Head of Compliance
  • Dr. Dragan Cicic M.D. (Age 61)
    MBA, Senior Vice President of Clinical Development
    Comp: $466.43k
  • Mr. Andrew Elnatan
    VP and Head of Regulatory Affairs, Chemistry, Manufacturing and Controls & Quality

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

SLS Stock Analysis - Frequently Asked Questions

Should I buy or sell SELLAS Life Sciences Group stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for SELLAS Life Sciences Group in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" SLS shares.
View SLS analyst ratings or view top-rated stocks.

What is SELLAS Life Sciences Group's stock price target for 2024?

1 analysts have issued 12 month price targets for SELLAS Life Sciences Group's stock. Their SLS share price targets range from $3.00 to $3.00. On average, they expect the company's share price to reach $3.00 in the next year. This suggests a possible upside of 100.7% from the stock's current price.
View analysts price targets for SLS or view top-rated stocks among Wall Street analysts.

How have SLS shares performed in 2024?

SELLAS Life Sciences Group's stock was trading at $1.06 on January 1st, 2024. Since then, SLS stock has increased by 41.0% and is now trading at $1.4950.
View the best growth stocks for 2024 here.

When is SELLAS Life Sciences Group's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our SLS earnings forecast.

How were SELLAS Life Sciences Group's earnings last quarter?

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) announced its quarterly earnings results on Friday, November, 12th. The company reported ($0.45) earnings per share for the quarter, missing analysts' consensus estimates of ($0.36) by $0.09.

What ETFs hold SELLAS Life Sciences Group's stock?

ETFs with the largest weight of SELLAS Life Sciences Group (NASDAQ:SLS) stock in their portfolio include Sprott Junior Copper Miners ETF (COPJ).Global X Copper Miners ETF (COPX).

When did SELLAS Life Sciences Group's stock split?

Shares of SELLAS Life Sciences Group reverse split before market open on Friday, November 8th 2019. The 1-50 reverse split was announced on Wednesday, November 6th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, November 7th 2019. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split.

How do I buy shares of SELLAS Life Sciences Group?

Shares of SLS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:SLS) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners
The “Perfect Storm” for Gold
Gold Safe Exchange
The Best AI Stock to Own in the World Today is Trading for Just $25
Banyan Hill Publishing
Tiny Biotech Stock Wins $75 Billion Patent
Behind the Markets
Biden’s $374B Giveaway Into This Sector
DTI
Your Money is Not Safe
American Alternative
He Is Giving Away Bitcoin
Crypto Swap Profits
The #1 Crypto for 2024
InvestorPlace
SHOCKING Crypto Leak…
Crypto 101 Media